跨损伤DNA合成及其在肿瘤治疗中的应用

神经药理学报 ›› 2014, Vol. 4 ›› Issue (5): 36-43.

跨损伤DNA合成及其在肿瘤治疗中的应用

黄敏, 唐铁山, 郭彩霞

1.中国科学院精准基因组医学重点实验室，中国科学院北京基因组研究所，北京，100101
2.生物膜与膜生物工程国家重点实验室，中国科学院动物研究所，北京，100101

出版日期:2014-10-26 发布日期:2015-01-20
通讯作者: 郭彩霞，女，研究员，博士生导师，研究方向：基因组不稳定性与疾病相关性研究，Tel: 010-84097646, E-mail: guocx@big.ac.cn
作者简介:黄敏，女，博士研究生，研究方向：跨损伤DNA合成通路与肿瘤耐药性，Tel/Fax:01084097856, E-mail: huangmin@big.ac.cn
基金资助:
国家自然科学基金项目（No.31471331, 31170730, 81300982, 31300880）

Translesion DNA Synthesis and Its Potential Role in Cancer Therapy

Huang Min, Tang Tie-shan, Guo Cai-xia

1. CAS, Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101
2. State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101

Online:2014-10-26 Published:2015-01-20
Contact: 郭彩霞，女，研究员，博士生导师，研究方向：基因组不稳定性与疾病相关性研究，Tel: 010-84097646, E-mail: guocx@big.ac.cn
About author:黄敏，女，博士研究生，研究方向：跨损伤DNA合成通路与肿瘤耐药性，Tel/Fax:01084097856, E-mail: huangmin@big.ac.cn
Supported by:
国家自然科学基金项目（No.31471331, 31170730, 81300982, 31300880）

摘要/Abstract

摘要： 跨损伤合成（translesion synthesis, TLS）是一种利用特殊的DNA聚合酶介导的修复过程，是细胞应答DNA损伤时的一种保守的耐受机制。由于TLS能使细胞耐受DNA损伤，降低肿瘤细胞对化疗药物或者放疗的敏感性，因此它可能是肿瘤产生耐药性或者辐射耐受性的潜在机制。因此，通过靶向跨损伤合成通路，可提高包括神经胶质瘤在内的多种肿瘤患者的治疗疗效。

关键词: 跨损伤合成, TLS聚合酶, 耐药性, 合成致死作用, 神经胶质瘤

Abstract: Translesion DNA synthesis (TLS) is an evolutionarily conserved mechanism of DNA damage tolerance in response to DNA damage, which utilizes specialized DNA polymerases to replicate damaged DNA templates. As TLS can tolerate DNA damages, decrease the sensitivity of cancer cells to chemotherapy drugs or ionizing radiation, it is a potential mechanism for cancers to develop drug resistance or radiation resistance. Therefore, it is plausible to target TLS pathway to enhance the therapeutic effect on patients with different tumors, including glioblastoma.

Key words: Translesion DNA synthesis, TLS polymerases, Drug resistance, Synthetic lethality, Glioblastoma

中图分类号:

R964

黄敏, 唐铁山, 郭彩霞. 跨损伤DNA合成及其在肿瘤治疗中的应用[J]. 神经药理学报, 2014, 4(5): 36-43.

Huang Min, Tang Tie-shan, Guo Cai-xia. Translesion DNA Synthesis and Its Potential Role in Cancer Therapy[J]. Acta Neuropharmacologica, 2014, 4(5): 36-43.

参考文献

[1] Guo Cai-xia, J Nicole Kosarek-Stancel, Tie-Shan Tang, et al. Y-family DNA polymerases in mammalian cells[J]. Cell Mol Life Sci, 2009, 66(14):2363-2381.

[2] Errol C Friedberg, Robert Wagner, Miroslav Radman. Specialized DNA polymerases, cellular survival, and the genesis of mutations [J]. Science, 2002, 296(5573):1627-1630.

[3] Philip A Knobel, Thomas M Marti. Translesion DNA synthesis in the context of cancer research [J]. Cancer Cell Int, 2011, 11: 39.

[4] Robert Evan Johnson, M T Washington, Shamsher Prakash, et al. Fidelity of human DNA polymerase eta [J]. J Biol Chem, 2000, 275(11): 7447-7450.

[5] Robert E Johnson, Satya Prakash, Louise Prakash. Efficient bypass of a thymine-thymine dimer by yeast DNA polymerase, Poleta [J]. Science, 1999, 283(5404): 1001-1004.

[6] Cruet-Hennequart S, Gallagher K, Sokol A M, et al. DNA polymerase eta, a key protein in translesion synthesis in human cells [J]. Subcell Biochem, 2010, 50: 189-209.

[7] Shilpy Sharma, J Kevin Hicks, Colleen L Chute, et al. REV1 and polymerase zeta facilitate homologous recombination repair [J]. Nucleic Acids Res, 2012, 40(2): 682-691.

[8] Tomoo Ogi, Siripan Limsirichaikul, Rene M Overmeer, et al. Three DNA polymerases, recruited by different mechanisms, carry out NER repair synthesis in human cells [J]. Mol Cell, 2010, 37(5): 714-727.

[9] Zhang Xiu-li, Lv Ling-na, Chen Qian, et al. Mouse DNA polymerase kappa has a functional role in the repair of DNA strand breaks [J]. DNA Repair (Amst), 2013, 12(5): 377-388.

[10] Lajos Haracska, Iidiko Unk, Robert Evan Johnson, et al. Stimulation of DNA synthesis activity of human DNA polymerase kappa by PCNA [J]. Mol Cell Biol, 2002, 22(3): 784-791.

[11] Errol C Friedberg. Reversible monoubiquitination of PCNA: A novel slant on regulating translesion DNA synthesis [J]. Mol Cell, 2006, 22(2): 150-152.

[12] Alan R Lehmann. Ubiquitin-family modifications in the replication of DNA damage [J]. FEBS Lett, 2011, 585(18): 2772-2779.

[13] Gargi Ghosal, Chen Jun-jie. DNA damage tolerance: a double-edged sword guarding the genome [J]. Transl Cancer Res, 2013, 2(3): 107-129.

[14] Koji Yoshimoto, Masahiro Mizoguchi, Nobuhiro Hata, et al. Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma [J]. Front Oncol, 2012, 2: 186.

[15] Tian Hui, Gao Zhen, Li Hui-zhong, et al. DNA damage response - A double-edged sword in cancer prevention and cancer therapy [J]. Cancer Lett, 2015, 358(1): 8-16.

[16] J Dirk Iglehart, Daniel P Silver. Synthetic lethality--a new direction in cancer-drug development [J]. N Engl J Med, 2009, 361(2): 189-191.

[17] Wang Zhi-feng, Wang Feng-li, Tang Tie-shan, et al. The role of PARP1 in the DNA damage response and its application in tumor therapy [J]. Front Med, 2012, 6(2): 156-164.

[18] Michael Metzger, Barry L Stoddard, Raymond J Monnat Jr. PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks [J]. DNA Repair (Amst), 2013, 12(7): 529-534.

[19] Masanao Miwa, Mitsuko Masutani. PolyADP-ribosylation and cancer [J]. Cancer Sci, 2007, 98(10): 1528-1535.

[20] Sung Ying-ju, Richard T Ambron. PolyADP-ribose polymerase-1 (PARP-1) and the evolution of learning and memory [J]. Bioessays, 2004, 26(12): 1268-1271.

[21] Li Mao, Zhang Zhuo, Donald L Hill, et al. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway [J]. Cancer Res, 2007, 67(5): 1988-1996.

[22] Christopher Calabrese, Robert Almassy, Stephanie Barton, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361 [J]. J Natl Cancer Inst, 2004, 96(1): 56-67.

[23] llirjana Bajrami, Jessica R Frankum, Asha Konde, et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity [J]. Cancer Res, 2014, 74(1): 287-297.

[24] Saqib U, Baig M S. Probing PARP1-inhibitor complexes for the development of novel inhibitors [J]. Cell Mol Biol (Noisy-le-grand), 2014, 60(3): 43-52.

[25] Xiong, T., H. Wei, X. Chen, et al. Effect of PARP1 inhibitor PJ34 on multi-drug resistance in human multiple myeloma cell line and its relationship with FA/BRCA pathway[J].J Medical Genetics, 2014, 31(3): 312-316.

[26] Na Zhen-kun, Peng Bo, Shukie Ng, et al. A small-molecule protein-protein interaction inhibitor of PARP1 that targets its BRCT domain [J]. Angew Chem Int Ed Engl, 2015, 54(8): 1-6.

[27] Philip A Knobel, IIyaN Kotov, Emanuela Felley-Bosco, et al. Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells [J]. Neoplasia, 2011, 13(10):961-970.

[28] Hans Joenje, Marieke Levitus, Quinten Waisfisz, et al. Complementation analysis in Fanconi anemia: assignment of the reference FA-H patient to group A [J]. Am J Hum Genet, 2000, 67(3): 759-762.

[29] Yamanaka Kinrin, Dorjsuren Dorjsuren, Robert L Eoff, et al. A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase kappa [J]. PLoS One, 2012, 7(10): e45032.

[30] John Wittschieben, Shalini C Reshmi, Susanne M Gollin, et al. Loss of DNA polymerase zeta causes chromosomal instability in mammalian cells [J]. Cancer Res, 2006, 66(1): 134-142.

[31] Linda Zander, Mats Bemark. Immortalized mouse cell lines that lack a functional Rev3 gene are hypersensitive to UV irradiation and cisplatin treatment [J]. DNA Repair (Amst), 2004, 3(7): 743-752.

[32] Jaime Gallego Perez-Larraya, Jean-Yves Delattre. Management of elderly patients with gliomas [J]. Oncologist, 2014, 19(12): 1258-1267.

[33] Brain M Alexander, Nancy Pinnell, Patrick Y Wen, et al. Targeting DNA repair and the cell cycle in glioblastoma [J]. J Neurooncol, 2012, 107(3): 463-477.

[34] Maricruz Rivera, Kumar Sukhdeo, Jennifer Yu. Ionizing radiation in glioblastoma initiating cells [J]. Front Oncol, 2013, 3: 74.

[35] Massimo Squatrito, Eric C Holland. DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance [J]. Cancer Res, 2011, 71(18): 5945-5949.

[36] Wang Hui-bo, Zhang Shu-yu, Wang Shuai, et al. REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy [J]. Neuro Oncol, 2009, 11(6): 790-802.

[37] Lin Xin-jian, Julie Trang, Tsuyoshi Okuda, et al. DNA polymerase accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair [J]. Clinical Cancer Research, 2006, 12(2): 563-568.

[38] Mark R Albertella, Alan Lau, Mark J O'Connor. The overexpression of specialized DNA polymerases in cancer [J]. DNA Repair (Amst), 2005, 4(5): 583-593.

[39] Chen Xie, Wang Hong-wei, Cheng Hong-bin, et al. RAD18 mediates resistance to ionizing radiation in human glioma cells [J]. Biochem Biophys Res Commun, 2014, 445(1): 263-268.

[40] Magda Bienko, Catherine M Green, Nicola Crosetto, et al. Ubiquitin-binding domains in Y-family polymerases regulate translesion synthesis [J]. Science, 2005, 310(5755): 1821-1824.

[41] Jun Huang, Michael S Y Huen, Hongtae Kim, et al. RAD18 transmits DNA damage signalling to elicit homologous recombination repair [J]. Nat Cell Biol, 2009, 11(5): 592-603.

[42] Han Jin-hua, Liu Ting, Michael S Huen, et al. SIVA1 directs the E3 ubiquitin ligase RAD18 for PCNA monoubiquitination [J]. J Cell Biol, 2014, 205(6): 811-827.

[43] Takahiro Oike, Yoshiyuki Suzuki, Ken-ichi Sugawara, et al. Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results [J]. PLoS One, 2013, 8(11): e78943.

[44] Priya U Kumthekar, Bryan D Macrie, Simran K Singh, et al. A review of management strategies of malignant gliomas in the elderly population [J]. Am J Cancer Res, 2014, 4(5): 436-444.